RESUMO
The present study aimed to investigate the binding of circulating mucin 1 (MUC1) antibody with serum MUC1 antigen in stage IV breast cancer. Serum samples of 61 patients with stage IV breast cancer and 64 patients with early-stage breast cancer were collected. The antiMUC1 antibody (IgG) and MUC1 antigen (cancer antigen 153; Ca153) were detected using an indirect enzyme-linked immunosorbent assay (IELISA) and ELISA, respectively. The MUC1 IgG affinity was detected using a urea degradation combining ELISA. Western blot analysis and an inhibition test were performed for verification of the binding of antiMUC1 IgG with MUC1 antigen, and their correlation was analyzed. The results showed that there was a negative correlation between antiMUC1 IgG and CA153 antigen in stage IV breast cancer when positive CA153 antigen and/or antiMUC1 IgG were selected (r=0.417; P=0.0044). The positive antiMUC1 IgG with positive Ca153 antigen was more common in stage IV breast cancer, compared with earlystage breast cancer (χ2=4.629; P=0.031), however, Ca153 antigen positivity was higher in stage IV breast cancer, compared with earlystage breast cancer (χ2=10.58; P=0.001). AntiMUC1 IgG was able to bind to the MUC1 antigen in stage IV breast cancer. No differences in the 8R-MUCPT inhibition ratio were found between the two groups (P=0.778), and there were no differences in the affinity of antiMUC1 IgG (P=0.873). In stage IV breast cancer, circulating antiMUC1 antibody was found to bind serum MUC1 antigen, although their compatibility was low. No significant difference was found in the affinity of the antiMUC1 antibody between stage IV breast cancer and earlystage breast cancer.
